Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
November 11 2021 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its senior leadership team will participate in the
following conferences:
- Guggenheim Healthcare Talks
Neuro/Immunology Virtual Conference: Hosting investor
meetings Monday, November 15 – Tuesday, November 16, 2021
- Evercore ISI 4th Annual
HealthCONx Virtual Conference: Presenting in a fireside
chat format on Wednesday, December 1, 2021, at 1:50 PM ET (Track 2)
and hosting investor meetings Tuesday, November 30 – Thursday,
December 2, 2021
To access a live webcast of the Evercore
fireside chat presentation, please visit the “Events &
Presentations” page within the Investors Relations section of
Longboard’s website at https://www.longboardpharma.com/. A replay
of the presentation will be available shortly after the completion
of the event and archived on the website for at least 30 days.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-HT2c receptor superagonist, with negligible observed
impact on 5-HT2b and 5-HT2a receptor subtypes, in development for
the potential treatment of seizures associated with developmental
and epileptic encephalopathies. Longboard is also evaluating LP143,
a centrally acting, full CB2 receptor agonist, in development for
the potential treatment of neurodegenerative diseases associated
with neuroinflammation caused by microglial activation, and LP659,
a centrally acting, S1P receptor subtypes 1 and 5 modulator, in
development for the potential treatment of central nervous system
neuroinflammatory diseases.
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Longboard’s participation in the upcoming conferences,
clinical and preclinical programs, ability to develop medicines,
and focus. For such statements, Longboard claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024